Search | Clinical Trials Finder

Conditions: Type 1 Diabetes Mellitus
Interventions: Sensor wear; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Sacramento, California • St. Petersburg, Florida + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Antithymocyte Globulin, Placebo (for ATG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 34 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Stanford, California + 17 more

Conditions: Type 1 Diabetes
Interventions: REMD-477, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetes Mellitus, Type 2, Food Insecurity, Diabetes Mellitus, Type 1
Interventions: Nutrition program; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin]); Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more

Conditions: Type 1 Diabetes, Pregnancy, High Risk
Interventions: Insulin; Drug
Lead sponsor: Gianna Wilkie; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Closed loop, Home glucose monitoring, Insulin pump, Continuous glucose monitor; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 2 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Continuous Glucose Monitoring System; Device
Lead sponsor: Senseonics, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Escondido, California • Idaho Falls, Idaho • San Antonio, Texas + 1 more

Conditions: Type 1 Diabetes
Interventions: Extended Wear Infusion Set, Standard Infusion Set; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type 1 Diabetes
Interventions: MAxIM, Usual Care; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 13 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 114 participants
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Interventions: Platelet Rich Plasma; Device
Lead sponsor: Estar Medical dba Medical Technologies, LTD; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Corpus Christi, Texas

Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: AU-007, Aldesleukin, Avelumab, Nivolumab; Drug
Lead sponsor: Aulos Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more

Conditions: Type 1 Diabetes
Interventions: Predictive Low Glucose Minimizer; Device
Lead sponsor: Animas Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 1 Diabetes
Interventions: Continuous Glucose Monitor (CGM); Device
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 1 Diabetes
Interventions: Resveratrol, Placebo; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin aspart SAR341402, Insulin aspart; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Little Rock, Arkansas • Denver, Colorado • West Des Moines, Iowa

Conditions: Diabetes Mellitus, Type 1
Interventions: Otelixizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Internet co-management module; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 39 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions: Biological Sample Collection; Other
Lead sponsor: New York Stem Cell Foundation Research Institute; Other
Eligibility: 30 Days and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2045
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Coin2Dose; Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Jacksonville, Florida • Kansas City, Missouri

Conditions: Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Ebselen, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

New Glucose Sensor Pediatric

STOP-T1D Low-Dose (ATG)

Effects of GRA in Patients With Type 1

Food Insecurity Reduction & Strategy Team

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features

Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy

Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care

NYSCF Scientific Discovery Biobank

Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens

The Multi-Sensor Distance Accuracy Study

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus